Activity Of Quinolines Research Articles

Chalcogen bonding in the solid-state structures of 1,3-bis(benzimidazoliumyl)benzene-based chalcogen-bonding donors.

1,3-Bis(benzimidazoliumyl)benzene-based chalcogen-bonding catalysts were previously successfully applied in different benchmark reactions. In one of those examples, i.e. the activation of quinolines, sulfur- and selenium-based chalcogen-bonding catalysts showed comparable properties, which is unexpected, as the selenium-containing catalysts should show superior catalytic properties due to the increased polarizability of selenium compared to sulfur. Herein, we present four crystal structures of the respective 1,3-bis(benzimidazoliumyl)benzene-based chalcogen-bonding catalyst containing sulfur (3S) and selenium (3Se, three forms) as Lewis acidic centres. The sulfur-containing catalyst shows weaker chalcogen bonding compared to its selenium analogue, as well as anion-π interactions. The selenium-based analogues, on the other hand, show stronger chalcogen-bonding motifs compared to the sulfur equivalent, depending on the crystallization conditions, but in every case, the intermolecular interactions are comparable in strength. Other interactions, such as hydrogen bonding and anion-π, were also observed, but in the latter case, the interaction distances are longer compared to those of the sulfur-based equivalent. The solid-state structures could not further explain the high catalytic activity of the sulfur-containing catalysts. Therefore, a comparison of their σ-hole depths from density functional theory (DFT) gas-phase calculations was performed, which are again in line with the previously found properties in the solid-state structures.

WITHDRAWN: Synthesis, DNA/protein binding, molecular docking and in vitro anticancer activity of quinoline based palladium(II) complexes

Abstract Two new palladium(II) complexes from 2-methyl 4-amino quinoline were synthesized and characterized by analytical, spectroscopic and X-ray diffraction techniques. The binding affinity and binding mode of the ligand and mononuclear complexes toward CT-DNA/BSA were determined by spectrophotometric titrations. From the binding studies, it has been found that the complexes interact strongly with CT-DNA and BSA. An in vitro cytotoxicity study of the compounds against human lung (A-549) and breast (MCF-7) cancer cell lines indicted better cytotoxic effect.

ChemInform Abstract: Remote C—H Activation of Quinolines Through Copper‐Catalyzed Radical Cross‐Coupling.

AbstractVarious N‐aryloyl or N‐alkyl protected 8‐aminoquinolines are efficiently sulfonylated in position 5 using a broad range of aryl or hetaryl sulfonyl chlorides.

Cover Picture: Remote C−H Activation of Quinolines through Copper‐Catalyzed Radical Cross‐Coupling (Chem. Asian J. 6/2016)

Cover Picture: Remote C−H Activation of Quinolines through Copper‐Catalyzed Radical Cross‐Coupling (Chem. Asian J. 6/2016)

Remote C-H Activation of Quinolines through Copper-Catalyzed Radical Cross-Coupling.

Achieving site selectivity in carbon-hydrogen (C-H) functionalization reactions is a formidable challenge in organic chemistry. Herein, we report a novel approach to activating remote C-H bonds at the C5 position of 8-aminoquinoline through copper-catalyzed sulfonylation under mild conditions. Our strategy shows high conversion efficiency, a broad substrate scope, and good toleration with different functional groups. Furthermore, our mechanistic investigations suggest that a single-electron-transfer process plays a vital role in generating sulfonyl radicals and subsequently initiating C-S cross-coupling. Importantly, our copper-catalyzed remote functionalization protocol can be expanded for the construction of a variety of chemical bonds, including C-O, C-Br, C-N, C-C, and C-I. These findings provide a fundamental insight into the activation of remote C-H bonds, while offering new possibilities for rational design of drug molecules and optoelectronic materials requiring specific modification of functional groups.

Cytotoxicity and induction of apoptosis by 4-amino-3-acetylquinoline in murine leukemia cell line L1210.

Nitrogen heterocyclic compounds are used in the pharmaceutical industry, in medicine and in agriculture for their biological activity. 4-Amino-3-acetylquinoline, a new synthetically prepared quinoline derivative, was the most effective compound in our primary cytotoxic screening. In this study, we evaluated cytotoxic/antiproliferative activity of quinoline using murine leukemia cell line L1210. Its ability to induce apoptosis was studied, too. Quinoline derivative acted cytotoxically on tumor cell line L1210, the IC(100) value were 50 microg/ml (for 24 h), 25 microg/ml (for 48 h) and 10 microg/ml (for 72 h). The IC(50) values was found to be less than 4 microg/ml, a limit put forward by the National Cancer Institute (NCI) for classification of he compound as a potential anticancer drug. The cytotoxic concentrations of 4-amino-3-acetyl quinoline induced morphological changes of L1210 cells and the apoptotic DNA fragmentation.

Hydrodenitrogenation of quinoline over Ni–Mo/Al 2O 3 catalyst modified with fluorine and phosphorus

In this paper, the effects of fluorine and phosphorus on the physical and chemical properties of Ni–Mo/Al 2O 3 catalysts and the hydrodenitrogenation (HDN) activity of quinoline were investigated. The acidity, pore structure, and dispersion of Mo of the catalysts were analyzed with TG-DTA, BET, and XRD techniques. The activities of hydrodenitrogenation and hydrogenation of the catalysts were investigated using hydrogenation of quinoline at high pressure in a micro-reactor. Experimental results verified that phosphorus can promote the formation of moderate and strong acidic sites, the dispersion of Mo, and the formation of the active phases; therefore, the hydrogenation activity of aromatic rings and the hydrogenolysis activity of C–N bonds increase. The hydrogenation and hydrogenolysis accelerate each other, which results in the increase of HDN activity. It is concluded that phosphorus is a promoter for HDN activity of the Ni–Mo/Al 2O 3 catalysts. Fluorine can promote the formation of weak and moderate acidic sites and the dispersion of Mo, but inhibit the formation of the active phases. Therefore, the hydrogenation activity of aromatic rings and the hydrogenolysis activity of C–N bonds decrease, which results in the decrease of HDN activity. It is concluded that fluorine is not a promoter for HDN activity of the Ni–Mo/Al 2O 3 catalysts. The possible promoting mechanism of fluorine and phosphorus for the Ni–Mo/Al 2O 3 catalyst is put forward and discussed.

Endogenous excitatory amino acids and glutamate receptor subtypes involved in the control of hypothalamic luteinizing hormone-releasing hormone secretion.

These studies were designed to evaluate the actions and relative potencies of different endogenous and excitatory amino acid (EAA) selective analogs on EAA-induced neuropeptide secretion as well as to analyze the receptor subtypes involved. For this purpose, different glutamate agonists were tested for their ability to evoke release of the hypothalamic neuropeptide LHRH from arcuate nucleus-median eminence (AN-ME) fragments incubated in vitro. Different glutamate agonists, i.e. 3-amino-3-hydroxy-5-methyl-isoxazole-4-propionic (AMPA), kainic, quisqualic, homocysteic (HCA), quinolinic (QUIN), N-methyl-D-aspartic (NMDA), and pyroglutamic (PYR) acids, elicited LHRH release from AN-ME fragments in vitro. Further evaluation of the range of activity of several of these compounds, both in terms of the dose inducing a half-maximal response and the LHRH-releasing effect at that particular dose, indicated that AMPA greater than HCA greater than QUIN greater than PYR, suggesting that non-NMDA receptors are primarily involved in EAA-induced LHRH release at the level of the AN-ME. Evaluation of the receptor types involved using two specific antagonists for NMDA and non-NMDA receptors, D,L-2-amino-7-phosphoheptanoic acid and 6,7-cyanoquinoxaline-2,3-dione, respectively, showed that the effects of AMPA and HCA on LHRH release can be completely blocked by 6,7-cyanoquinoxaline-2,3-dione, whereas QUIN activity was blocked by D,L-2-amino-7-phosphoheptanoic acid. The effects of PYR on LHRH release were abolished by both receptor blockers. The metabotropic receptor agonist trans-1-amino-cyclopentyl-1,1,3-dicarboxylic acid was not active in eliciting LHRH secretion. The data indicate that endogenous substances active at EAA receptor sites, such as HCA, QUIN, and PYR, can significantly increase the secretion of the neuropeptide LHRH and, thus, may participate in the physiological regulation of the activity of this important neuroendocrine neuronal system. In addition, the results suggest that non-NMDA receptor sites may be preferentially activated at lower ligand concentrations, although NMDA receptors may also be involved in the response to certain endogenous agonists.